• Investing
  • Stock
  • Economy
  • Editor’s Pick
Portfolio Performance Today
Stock

Eli Lilly pulls ahead of Novo in obesity drug gold rush as new players crowd in

by May 17, 2025
by May 17, 2025

The global weight-loss drug market, once dominated by Novo Nordisk, is undergoing a dramatic transformation.

On Friday, the Danish pharmaceutical giant announced it would replace its long-serving chief executive, Lars Fruergaard Jorgensen, as the company faces mounting pressure from rivals and a sharp slide in its stock value.

Novo’s shares have fallen 50% over the past year, a stunning reversal for the maker of Wegovy and Ozempic, two of the most recognisable names in obesity and diabetes care.

Analysts expect the weight-loss drug market to expand significantly in the next decade, potentially reaching $100 billion globally.

Jorgensen’s ouster signals deeper turmoil at the heart of the fast-evolving market, where GLP-1 drugs—once seen as miracle treatments—are now facing stiffer competition and growing scrutiny from insurers and policymakers.

Eli Lilly’s rise reshapes market leadership

The most formidable challenger has emerged in the form of US-based Eli Lilly, whose GLP-1 injection Zepbound has steadily gained market share against Novo’s Wegovy.

Lilly’s latest clinical data has only solidified its momentum.

A recent late-stage trial showed that orforglipron, the company’s experimental pill, helped diabetes patients lose nearly 8% of their body weight in 40 weeks—beating Ozempic’s performance in a similar cohort.

Lilly also boasts retatrutide, a weekly injection that delivered 24.2% weight loss in a mid-stage trial, one of the strongest results in the sector so far.

The company expects to seek approval for orforglipron by year-end and continues to invest aggressively, including a recent deal with Chinese biotech Laekna to develop a muscle-preserving obesity drug.

Novo races to catch up with next-generation drugs

To reclaim lost ground, Novo Nordisk is banking on new treatments.

It is developing amycretin in both pill and injectable form.

Early trial data suggest significant weight-loss potential, with the injectable version helping patients lose 22% of their body weight in 36 weeks.

The company is also pushing forward with CagriSema, though late-stage trial results have underwhelmed, falling short of internal benchmarks.

Novo hopes to submit CagriSema for regulatory approval in early 2026.

It has also broadened its pipeline through partnerships, including a $2 billion licensing agreement with United Laboratories for a triple-hormone targeting obesity drug.

Source: The Economist

Roche, Amgen also join the bandwagon

Lilly and Novo are no longer alone in the race. A host of major pharmaceutical companies and biotech firms are piling into the obesity space, lured by the multibillion-dollar market opportunity.

Pfizer recently dropped out after safety concerns in a trial involving danuglipron, its oral GLP-1 candidate.

But others are forging ahead. Roche has made big bets, acquiring Zealand Pharma’s petrelintide and Carmot Therapeutics’ CT-388, both GLP-1-based drugs, for a combined $8 billion.

Early data on Carmot’s second candidate also appears promising.

Amgen’s MariTide, an experimental drug that led to 20% weight loss in a mid-stage trial, is set to begin late-stage studies by mid-year.

Analysts note that the drug’s side effects may be more pronounced than competitors’, but its efficacy places it among the front-runners.

Merck, AstraZeneca, smaller firms also seek a slice of the market

Pharma giants traditionally absent from obesity treatments are now seeking a slice of the market.

In December, Merck struck a $2 billion licensing deal for a GLP-1 pill developed by Hansoh Pharma.

AstraZeneca’s licensed candidate AZD5004 has cleared early safety hurdles and is in mid-stage trials.

Smaller firms are also showing potential. Altimmune’s pemvidutide posted a 15.6% average weight loss in trials, although with notable gastrointestinal side effects.

Viking Therapeutics reported nearly 15% weight loss in 13 weeks with its injectable VK2735, and Zealand Pharma’s petrelintide posted 8.6% average weight loss in an early study.

Structure Therapeutics, meanwhile, has shown modest success with its oral candidate GPCR, delivering 6.2% weight loss over 12 weeks.

While not as potent as rivals, the convenience of an oral drug remains attractive to patients and investors alike.

Access remains an issue

Despite scientific advancements, access to these drugs remains a critical issue.

Employers are struggling with rising health coverage costs, leading many to exclude weight-loss drugs from their insurance plans.

Medicare still does not reimburse for obesity treatments in most cases.

A Biden administration plan to expand coverage was recently struck down by the Trump administration, leaving most patients to pay out of pocket. At an average of $500 per month, affordability remains a barrier for millions.

The post Eli Lilly pulls ahead of Novo in obesity drug gold rush as new players crowd in appeared first on Invezz

0 comment
0
FacebookTwitterPinterestEmail

previous post
What made Cox Communications say ‘yes’ to a buyout after years of resistance?
next post
Archer Aviation wins LA28 Olympics contract: is ACHR grossly undervalued?

Related Posts

Asian markets open: most futures lower; Sensex to...

June 6, 2025

Here’s why the Nifty 50 Index may surge...

June 6, 2025

Circle stock price prediction: is CRCL a good...

June 6, 2025

Trump-Musk fallout risks SpaceX deals, Tesla’s standing, and...

June 6, 2025

European markets open: Stoxx 600 flat ahead of...

June 6, 2025

Musk, Trump dial back feud as White House...

June 6, 2025

XRP slips 2.5% to $2.14 as Trump-Musk clash...

June 6, 2025

China’s May export growth seen slowing to 5.0%...

June 6, 2025

FTSE 100 Index shares of 2025: Rolls-Royce, Fresnillo,...

June 6, 2025

Citi downgrades CEG stock despite Constellation Energy’s big...

June 5, 2025

Stay updated with the latest news, exclusive offers, and special promotions. Sign up now and be the first to know! As a member, you'll receive curated content, insider tips, and invitations to exclusive events. Don't miss out on being part of something special.

By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

Recent Posts

  • Relative Drug Pricing is Bad Medicine

    June 6, 2025
  • Want to Fix Medicaid? Look to Milton Friedman

    June 6, 2025
  • Want to Fix Medicaid? Look to Milton Friedman

    June 6, 2025
  • Relative Drug Pricing is Bad Medicine

    June 6, 2025
  • Asian markets open: most futures lower; Sensex to open flat as RBI policy decision looms

    June 6, 2025
  • Here’s why the Nifty 50 Index may surge after the RBI rate cut

    June 6, 2025

Editors’ Picks

  • 1

    Walmart earnings preview: What to expect before Thursday’s opening bell

    February 20, 2025
  • 2

    Meta executives eligible for 200% salary bonus under new pay structure

    February 21, 2025
  • 3

    New FBI leader Kash Patel tapped to run ATF as acting director

    February 23, 2025
  • 4

    Anthropic’s newly released Claude 3.7 Sonnet can ‘think’ as long as the user wants before giving an answer

    February 25, 2025
  • 5

    Elon Musk says federal employees must fill out productivity reports or resign

    February 23, 2025
  • 6

    Nvidia’s investment in SoundHound wasn’t all that significant after all

    March 1, 2025
  • 7

    Cramer reveals a sub-sector of technology that can withstand Trump tariffs

    March 1, 2025

Categories

  • Economy (1,373)
  • Editor's Pick (143)
  • Investing (165)
  • Stock (882)
  • About us
  • Contact us
  • Privacy Policy
  • Terms & Conditions

Copyright © 2025 Portfolioperformancetoday.com All Rights Reserved.

Portfolio Performance Today
  • Investing
  • Stock
  • Economy
  • Editor’s Pick
Portfolio Performance Today
  • Investing
  • Stock
  • Economy
  • Editor’s Pick
Copyright © 2025 Portfolioperformancetoday.com All Rights Reserved.

Read alsox

JEPI and JEPQ ETFs: Scorecard as S&P...

April 1, 2025

Uber stock price analysis: buy the Tesla...

May 30, 2025

Stoxx 50 index forms bullish pattern ahead...

March 28, 2025